10x Genomics, Inc.
About 10x Genomics, Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $642.8M
- Net income
- -$43.5M
- Total assets
- $1.0B
- Market cap
- $3.9B
- Gross margin
- 69.1%
- Operating margin
- -9.5%
- Net margin
- -6.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $642.8M
- Cost of revenue
- $198.9M
- Gross profit
- $443.9M
- Operating expenses
- $504.9M
- Operating income
- -$61.0M
- Income tax
- $3.6M
- Net income
- -$43.5M
- EPS (basic)
- $-0.35
- EPS (diluted)
- $-0.35
Balance sheet
- Total assets
- $1.0B
- Current assets
- $684.5M
- Total liabilities
- $245.0M
- Current liabilities
- $153.5M
- Shareholders’ equity
- $796.3M
Cash flow
- Operating cash flow
- $136.1M
- Investing cash flow
- -$13.4M
- Financing cash flow
- $6.8M
- Net cash flow
- $129.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.9B
- EPS (diluted)
- $-0.35
- Shares outstanding
- 135.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 12, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $43.5M in FY2025.
- Revenue grew 31% from FY2021 to FY2025.
- Gross margin of 69.1%, net margin -6.8%.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review 10x Genomics, Inc..
Write a review
News about 10x Genomics, Inc.
News & sentiment via Polygon.io
